ABSTRACT
No disponible
No disponible
Subject(s)
Humans , Male , Aged, 80 and over , Hematoma , Thoracic Wall/injuries , Pleural Diseases , Radiography, Thoracic/methods , Incidental FindingsABSTRACT
Presentamos el caso de una mujer de 52 años con el antecedente de infecciones respiratorias de repetición desde la infancia, que presenta una fístula broncoesofágica (FBE) congénita diagnosticada de forma incidental a raíz de la aparición de disfagia en los últimos meses. Los estudios radiológicos y manométricos demuestran la asociación con megaesófago y acalasia. Se confirmó el diagnóstico de FBE en bronquio principal izqdo. gracias a un tránsito con gastrografín, esofagoscopia y fibrobroncoscopia. El tratamiento fue quirúrgico mediante toracotomía posterolateral izquierda, procediendo a la resección del trayecto fistuloso e invaginación del muñón con sutura de muscularis esofágica (AU)
We report the case of a 52-year-old woman with a history of recurrent respiratory infections, which presents a congenital bronchoesophageal fistula (BEF) incidentally diagnosed after the appearance of dysphagia in the last months. The radiological and manometric studies demonstrate the association with megaesophagus and achalasia. Diagnosis of BEF in the left main bronchus was confirmed thanks to an esophagogram, esophagoscopy and fiberoptic bronchoscopy. The surgical treatment was carried out through a left posterolateral thoracotomy, proceeding to resection of the fistula and invagination of the stump with suture of esophageal muscularis (AU)
Subject(s)
Humans , Tuberculosis, Pulmonary/history , Respiratory Tract Diseases/history , History of MedicineABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Teratoma/diagnosis , Mediastinal Neoplasms/diagnosis , Diagnosis, Differential , Aneurysm/diagnosis , Echocardiography , Tomography, X-Ray ComputedABSTRACT
La vareniclina, agonista parcial de los receptores nicotínicos, se añade en el momento actual al arsenal terapéutico de primera línea utilizable para ayudar a dejar de fumar. Se trata de un fármaco bien tolerado, seguro y de eficacia probada con escasos efectos secundarios (AU)
Vareniclin, partially agonist of the nicotinic receptors, is added to the therapies collection of drugs for the front line in the current days, useful when the stop smoking aid is sought. It is a well tolerated drug, sure and with efficiency well proved, just with few secondary effects (AU)
Subject(s)
Humans , Smoking/drug therapy , Nicotinic Agonists/pharmacology , Tobacco Use Cessation , Treatment OutcomeABSTRACT
No disponible
No disponible
Subject(s)
Humans , Smoking/legislation & jurisprudence , Civil Rights/legislation & jurisprudence , Tobacco Smoke Pollution/legislation & jurisprudence , Public HealthABSTRACT
El tratamiento del tabaquismo ha avanzado considerablemente en las últimas dos décadas, hoy disponemos , como primera línea de tratamiento, de chicles, parches, pastillas para chupar de nicotina, a diferentes dosis y en una amplia variedad de sabores además del bupropión. Mucha medicación y una vacuna antinicotina, se encuentran en la actualidad en diferentes fases de estudio con la esperanza de que en el futuro estén disponibles varios fármacos para ayudar a dejar de fumar. El futuro del tratamiento de la adicción al tabaco será probablemente más individualizado, empleando la combinación de varios fármacos que actúen en diferentes lugares a nivel cerebral y profundizándose el conocimiento que actualmente se tiene de la farmacogenética y la farmacogenómica aplicada a los fármacos empleados para ayudar a dejar de fumar (AU)
The treatment of tobacco addiction has notoriously advanced in the last two decades, today we can use, as a fist line of treatment, chewing gums, patchs, tablets of nicotine to suck ,with different doses and with a great variety of tastes, and so the bupropione. Many drugs and a nicotine vaccine are currently being developed, in different stages of study, with the hope that, in the future, various drugs will be available to help in smoking addiction leaving. The future treatment of the tobacco addiction is supposed to be more individualized, using mixes of various drugs, acting in different cerebral areas and helping to have a deeper knowledge a pharmacogenetics and applied pharmacogenomics of such drugs (AU)
Subject(s)
Humans , Smoking/drug therapy , Smoking Cessation/methods , Smoking/psychology , Smoking/prevention & control , Bupropion/therapeutic use , Smoking Cessation/psychologyABSTRACT
OBJECTIVE: The aim of this study was to characterize the leading topics in respiratory system in Spain through a bibliometric analysis. MATERIAL AND METHOD: For identify and characterize the performance of the different research topics in respiratory system in Spain, we compile the production using a journal that turn out representative of a broad group of researcher. In this sense the journal Archivos de Bronconeumología is the most important publication in Spanish language of this field. RESULTS: A total of 2198 articles published in Archivos Bronconeumología from 1970 to 2000 were analyzed. In each three decades, we did not found differences except in the productivity index in oncology in the eighty decade and in respiratory failure and sleep disturbance (RFSD) and oncology areas in the ninetieth decade and in the Price index (consumption indicators) in the diagnostic and therapeutic techniques area in seventy decade. When we compare the productivity index of each subject areas between decades, we found a significant production increase in the ninetieth decade in asthma, RFSD, tuberculosis, non tuberculosis infection, circulation, oncology, pleural disease and interstitial areas versus the same in seventy decade, and also, we found significant differences between ninetieth and eighty decades in the asthma, RFSD, non tuberculosis infection, circulation and pleural disease areas. Tuberculosis area maintains an insularity index higher than the other areas. We also found a progressive increase in the insularity index of RFSD, non tuberculosis infection, oncology and interstitial disease areas. CONCLUSIONS: In general all the indicators maintains stable although the more productivity topics were respiratory failure and sleep disturbances, and oncology. The productivity has increased in asthma, respiratory failure and sleep disturbances, tuberculosis, non - tuberculosis respiratory infections, oncology, pulmonary circulation, pleura and interstitial disease.
Subject(s)
Periodicals as Topic/statistics & numerical data , Respiratory Tract Diseases , Humans , Publishing/statistics & numerical data , Pulmonary Medicine/statistics & numerical data , SpainABSTRACT
No disponible
Subject(s)
Humans , Tobacco Use Disorder/adverse effects , Tobacco Use Disorder/complications , Sleep Apnea Syndromes/etiology , Pulmonary Disease, Chronic Obstructive/etiology , Tobacco Use Disorder/epidemiology , Snoring/etiologyABSTRACT
No disponible
Subject(s)
Humans , Pulmonary Disease, Chronic Obstructive/therapy , Tobacco Use Disorder/therapy , Tobacco Use Cessation , Pulmonary Disease, Chronic Obstructive/complicationsABSTRACT
No disponible
Subject(s)
Humans , Students, Nursing , Students, Medical , Tobacco Use Disorder , Spain , Rehabilitation , Respiration Disorders , Lung DiseasesABSTRACT
We present a case of amiodarone pulmonary toxicity, special emphasis is given to the radiological features because the presence of pulmonary nodules with interstitial and alveolar abnormalities. Due to a treatment with amiodarone, the patient developed few symptoms, with a low maintenance dose of 200 mg/day.
Subject(s)
Amiodarone/adverse effects , Anti-Arrhythmia Agents/adverse effects , Lung Diseases, Interstitial/chemically induced , Lung Diseases, Interstitial/diagnostic imaging , Aged , Female , Humans , RadiographyABSTRACT
To assess clinical and bronchoscopic evolution as well as outcome in patients treated with high dose rate (HDR) endobronchial brachytherapy in order to determine its effectiveness for treating malignant airway obstruction. From May 1993 to January 1996, 10 patients (9 men and 1 woman) with bronchogenic carcinoma received 24 HDR endobronchial treatments. The mean age was 61.9 years (range 34 to 78 years). Inclusion criteria were, for palliative treatment, incurable endobronchial cancer, and, for curative treatment, residual tumor in the margins after resection, or endobronchial tumor that could not be treated surgically. Exclusion criteria were site of lesion unsuitable for placement of the brachytherapy catheter, life expectancy less than two months, Karnofsky index less than 60 or absence of signed consent from the patient. Response criteria was either complete or partial for symptoms and endobronchial tumor. Ten patients received 24 HDR endobronchial treatment from and HDR source of I192 radiation with remote afterloading. A flexible bronchoscope was passed down the bronchial tree toward the area affected by the tumor. At intervals of one week, four separate fractions between 5 and 10 Gy were delivered to a depth of 0.5 to 1 cm and a length of 1 to 5 cm. One month after the last session, each patient underwent endoscopic examination with removal of a histology specimen. Response was considered complete based on clinical signs in 66%; response was complete based on endoscopy in 50%. Three patients died within the first year after treatment and one patient did not return for a follow-up examination. Five patients who had been followed for less than one year were still living. The remaining patient was living 18 months after treatment. All tolerated the treatments well, showing neither early nor late complications. HDR endobronchial brachytherapy is effective both for preventing and relieving malignant endobronchial obstruction. Response to therapy is good, as shown by clinical symptoms and endobronchial examination. HDR endobronchial brachytherapy can cure in carefully selected patients.
Subject(s)
Adenocarcinoma/radiotherapy , Brachytherapy , Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Small Cell/radiotherapy , Carcinoma, Squamous Cell/radiotherapy , Lung Neoplasms/radiotherapy , Adult , Aged , Brachytherapy/methods , Female , Follow-Up Studies , Humans , Lung Neoplasms/diagnostic imaging , Male , Middle Aged , Palliative Care , Radiography, Thoracic , Radiotherapy Dosage , Time FactorsABSTRACT
Patient with atypical carcinoid with pleural effusion, diffuse pulmonary involvement and subcutaneous nodule, bone metastases and mediastinal metastases as the first presentation of the carcinoid. Atypical carcinoid is defined as a higher incidence of metastases, and a worse prognosis.
